Sellas Life Sciences shows more data from trastuzumab +/- nelipepimut-S trial

Sellas Life Sciences announced additional data on patterns of clinical relapses, as well as results from a preplanned secondary efficacy analysis across various predefined subgroups from the prospective, randomized, single-blinded, controlled Phase 2b independent investigator-sponsored clinical trial of the combination of trastuzumab +/- nelipepimut-S targeting HER2 low-expressing breast cancer patient cohorts at the San Antonio Breast Cancer Symposium, or SABCS. These new data show a decrease in the total number of clinically detectable relapses with the combination of NPS + trastuzumab vs. trastuzumab alone, p-value 0.004, which represents a 72.5% relative reduction in risk of relapse across time with a median follow up of 26.1 months in favor of the combination arm. Results from a planned analysis of the difference in disease free survival, or DFS, outcomes between the two arms of the study in prespecified TNBC patient subgroups showed a clinically meaningful and statistically significant effect in these subgroups in favor of the NPS plus trastuzumab combination arm. There was an average decrease of 84.2% in the relative risk of relapse or death at 24 months across these four subgroups of TNBC patients treated with NPS plus trastuzumab vs trastuzumab alone.
https://thefly.com/landingPageNews.php?id=2832965